{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "209bce71",
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip install pandas sentence-transformers scikit-learn ipywidgets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f3a9a5b4",
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip install langchain langchain-community"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "bdaf8806",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import re \n",
    "from collections import Counter \n",
    "import ipywidgets as widgets\n",
    "from IPython.display import display, clear_output\n",
    "import math\n",
    "from langchain.embeddings import HuggingFaceEmbeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "6e8e253d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# CONFIG\n",
    "\n",
    "CSV_FILENAME = 'drug_data.csv' \n",
    "\n",
    "# TEXT_COLUMNS_FOR_EMBEDDING = ['Cancer Type', 'Brief Study Summary', 'Formatted Study Results']\n",
    "TEXT_COLUMNS_FOR_EMBEDDING = ['Cancer Type']\n",
    "\n",
    "OUTCOME_COLUMNS = ['Treatment_OS', 'Control_OS', 'OS_Improvement (%)', 'Treatment_PFS', 'Control_PFS', 'PFS_Improvement (%)']\n",
    "\n",
    "RELEVANCE_SCORE_THRESHOLD = 0.5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "c949e0c5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# HELPER FUNCTIONS\n",
    "\n",
    "# Basic text cleaning // to improve semanting matching quality\n",
    "def clean_text(text):\n",
    "    if isinstance(text, str):\n",
    "        text = text.lower()\n",
    "        text = re.sub(r'[^a-z0-9\\s-]', '', text) # Remove special characters, except hyphens\n",
    "        text = re.sub(r'\\s+', ' ', text).strip() # Remove extra spaces\n",
    "        return text\n",
    "    return ''\n",
    "\n",
    "\n",
    "def parse_time_to_months(time_str):\n",
    "    # Parses strings like '18.6 months', '2.1 years', 'N/A', 'Not reached' into numerical months.\n",
    "    # Returns None for non-numeric or unclear values.\n",
    "\n",
    "    if isinstance(time_str, (int, float)):\n",
    "        return float(time_str) # Assume it's already in months if numeric onlu\n",
    "    \n",
    "    if not isinstance(time_str, str):\n",
    "        return None\n",
    "\n",
    "    time_str = time_str.strip().lower()\n",
    "\n",
    "    # Handle specific non-numeric values\n",
    "    if time_str in ['n/a', 'not applicable', 'not reported', 'not reached', 'nr']:\n",
    "        return None\n",
    "\n",
    "    # Look for numbers followed by units\n",
    "    match = re.match(r'(\\d+(\\.\\d+)?)\\s*(month|year)s?', time_str)\n",
    "    if match:\n",
    "        value = float(match.group(1))\n",
    "        unit = match.group(3)\n",
    "        if unit == 'year':\n",
    "            return value * 12\n",
    "        elif unit == 'month':\n",
    "            return value\n",
    "\n",
    "    return None # Could not parse\n",
    "\n",
    "def parse_improvement_percentage(perc_str):\n",
    "    # Parses strings like '41.80%', 'Not statistically significant' into numerical percentage.\n",
    "    # Returns None for non-numeric or 'Not statistically significant'.\n",
    "\n",
    "    if isinstance(perc_str, (int, float)):\n",
    "         return float(perc_str) # Assume it's already a percentage as a float (e.g., 41.8)\n",
    "    if not isinstance(perc_str, str):\n",
    "        return None\n",
    "\n",
    "    perc_str = perc_str.strip().lower()\n",
    "\n",
    "    if perc_str in ['n/a', 'not applicable', 'not reported', 'not statistically significant', 'nss']:\n",
    "        return None\n",
    "\n",
    "    # Look for number potentially ending with %\n",
    "    match = re.match(r'(\\d+(\\.\\d+)?)\\s*%', perc_str)\n",
    "    if match:\n",
    "        return float(match.group(1))\n",
    "\n",
    "    # Handle just a number string without %\n",
    "    num_match = re.match(r'^(\\d+(\\.\\d+)?)$', perc_str)\n",
    "    if num_match:\n",
    "        return float(num_match.group(1)) \n",
    "\n",
    "    return None # Could not parse\n",
    "\n",
    "# those with None values goes to end\n",
    "def sort_key_with_none(value, reverse=True):\n",
    "    if value is None or (isinstance(value, float) and math.isnan(value)):\n",
    "        return float('-inf') if reverse else float('inf')\n",
    "    return value"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "a8c8a3ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading data from drug_data.csv...\n",
      "Data loaded successfully.\n"
     ]
    }
   ],
   "source": [
    "print(f\"Loading data from {CSV_FILENAME}...\")\n",
    "try:\n",
    "    df = pd.read_csv(CSV_FILENAME)\n",
    "    print(\"Data loaded successfully.\")\n",
    "except FileNotFoundError:\n",
    "    print(f\"Error: {CSV_FILENAME} not found. Please make sure the CSV file is in the same directory.\")\n",
    "    exit()\n",
    "\n",
    "# Preprocess text columns for embedding\n",
    "# Combine relevant text columns\n",
    "df['combined_text_for_embedding'] = df[TEXT_COLUMNS_FOR_EMBEDDING].fillna('').agg(' '.join, axis=1)\n",
    "df['combined_text_cleaned_for_embedding'] = df['combined_text_for_embedding'].apply(clean_text)\n",
    "\n",
    "# Parse Outcome Metrics into numerical format\n",
    "df['Treatment_OS_Months_Parsed'] = df['Treatment_OS'].apply(parse_time_to_months)\n",
    "df['Control_OS_Months_Parsed'] = df['Control_OS'].apply(parse_time_to_months)\n",
    "\n",
    "# Calculate numerical OS Improvement where possible\n",
    "df['Calculated_OS_Improvement_Months'] = df.apply(\n",
    "    lambda row: row['Treatment_OS_Months_Parsed'] - row['Control_OS_Months_Parsed']\n",
    "    if row['Treatment_OS_Months_Parsed'] is not None and row['Control_OS_Months_Parsed'] is not None else None,\n",
    "    axis=1\n",
    ")\n",
    "\n",
    "df['OS_Improvement_Percentage_Parsed'] = df['OS_Improvement (%)'].apply(parse_improvement_percentage)\n",
    "df['PFS_Improvement_Percentage_Parsed'] = df['PFS_Improvement (%)'].apply(parse_improvement_percentage)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "7b055150",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Loading Sentence Transformer model...\n",
      "Model loaded successfully.\n",
      "\n",
      "Generating text embeddings for drug data...\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "bf180c808ec64539b73ed0a1b74245e8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Batches:   0%|          | 0/9 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Embeddings generated.\n"
     ]
    }
   ],
   "source": [
    "# Load Sentence Transformer model\n",
    "print(\"\\nLoading Sentence Transformer model...\")\n",
    "\n",
    "try:\n",
    "    model = SentenceTransformer('all-MiniLM-L6-v2') # for quic test\n",
    "    # model = SentenceTransformer('biobert-v1.1') \n",
    "    print(\"Model loaded successfully.\")\n",
    "except Exception as e:\n",
    "    print(f\"Error loading Sentence Transformer model: {e}\")\n",
    "    exit()\n",
    "\n",
    "# Generate embeddings for the combined text\n",
    "print(\"\\nGenerating text embeddings for drug data...\")\n",
    "drug_embeddings = model.encode(df['combined_text_cleaned_for_embedding'].tolist(), show_progress_bar=True, convert_to_numpy=True)\n",
    "print(\"Embeddings generated.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "ec601e8e",
   "metadata": {},
   "outputs": [],
   "source": [
    "def find_relevant_drugs(df: pd.DataFrame, drug_embeddings: np.ndarray, model: SentenceTransformer,\n",
    "                        user_cancer_type_raw: str, user_stage_raw: str, user_biomarkers_raw: str,\n",
    "                        relevance_threshold: float = RELEVANCE_SCORE_THRESHOLD):\n",
    "   \n",
    "    # Clean user inputs\n",
    "    user_cancer_type_cleaned = clean_text(user_cancer_type_raw)\n",
    "    user_stage_cleaned = clean_text(user_stage_raw)\n",
    "    user_biomarkers_cleaned_list = [clean_text(b.strip()) for b in user_biomarkers_raw.split(',') if b.strip()]\n",
    "\n",
    "    # Create the full user query string for embedding\n",
    "    # Include all parts of the user's profile for semantic matching\n",
    "    user_query_text = f\"{user_cancer_type_cleaned} {user_stage_cleaned} {' '.join(user_biomarkers_cleaned_list)}\"\n",
    "\n",
    "    print(f\"\\n--- Searching for drugs for profile: {user_query_text.strip()} ---\")\n",
    "    if not user_query_text.strip():\n",
    "         print(\"Warning: User query is empty after cleaning. Cannot perform search.\")\n",
    "         return []\n",
    "\n",
    "\n",
    "    try:\n",
    "        user_embedding = model.encode(user_query_text, convert_to_numpy=True)\n",
    "    except Exception as e:\n",
    "        print(f\"Error generating user query embedding: {e}\")\n",
    "        return []\n",
    "\n",
    "    potential_results = []\n",
    "\n",
    "    # Iterate through the pre-processed DataFrame and calculate semantic similarity\n",
    "    for index, row in df.iterrows():\n",
    "        # Calculate Semantic Similarity\n",
    "        semantic_sim = cosine_similarity([user_embedding], [drug_embeddings[index]])[0][0]\n",
    "\n",
    "        # Filter by Relevance Threshold\n",
    "        if semantic_sim >= relevance_threshold:\n",
    "            potential_results.append({\n",
    "                'index': index,\n",
    "                'semantic_similarity': semantic_sim,\n",
    "                'calculated_os_improvement_months': row['Calculated_OS_Improvement_Months'],\n",
    "                'os_improvement_percentage_parsed': row['OS_Improvement_Percentage_Parsed'],\n",
    "                'pfs_improvement_percentage_parsed': row['PFS_Improvement_Percentage_Parsed'],\n",
    "                # Include original data needed for display/explanation\n",
    "                'Drug Name': row['Drug Name'],\n",
    "                'Cancer Type': row['Cancer Type'],\n",
    "                'Brief Study Summary': row['Brief Study Summary'],\n",
    "                'Treatment_OS': row['Treatment_OS'],\n",
    "                'Control_OS': row['Control_OS'],\n",
    "                'OS_Improvement (%)': row['OS_Improvement (%)'],\n",
    "                'Treatment_PFS': row['Treatment_PFS'],\n",
    "                'Control_PFS': row['Control_PFS'],\n",
    "                'PFS_Improvement (%)': row['PFS_Improvement (%)'],\n",
    "            })\n",
    "\n",
    "    # --- Ranking ---\n",
    "    # Sort results (which are already filtered by the threshold):\n",
    "    \n",
    "    # 1. Primarily by Semantic Similarity (descending) - This implicitly handles cancer type, stage, biomarkers matching\n",
    "    # 2. Secondly by Calculated OS Improvement in months (descending, handling None)\n",
    "    # 3. Secondarily by whether OS Improvement % is a number (numeric first)\n",
    "    # 4. Thirdly by OS Improvement % value (descending, handling None)\n",
    "    \n",
    "\n",
    "\n",
    "    potential_results.sort(key=lambda x: (\n",
    "        x['semantic_similarity'], # 1: Semantic Similarity (desc)\n",
    "        sort_key_with_none(x['calculated_os_improvement_months'], reverse=True), # 2: Calc OS diff months (desc)\n",
    "        sort_key_with_none(x['os_improvement_percentage_parsed'] is not None, reverse=True), # 3: Has numeric OS% (True first)\n",
    "        sort_key_with_none(x['os_improvement_percentage_parsed'], reverse=True), # 4: OS% value (desc)\n",
    "        \n",
    "\n",
    "    ), reverse=True) \n",
    "\n",
    "    formatted_output = []\n",
    "    # --- Present Results ---\n",
    "    print(f\"\\nFound {len(potential_results)} potentially relevant drugs (Semantic Similarity >= {relevance_threshold:.2f}):\")\n",
    "\n",
    "    if not potential_results:\n",
    "        print(\"No relevant drugs found for this profile based on the specified threshold.\")\n",
    "    else:\n",
    "        # Prepare formatted output\n",
    "        \n",
    "        for i, result in enumerate(potential_results):\n",
    "            explanation_parts = []\n",
    "            explanation_parts.append(f\"Relevance Score (Semantic Sim): {result['semantic_similarity']:.4f}\")\n",
    "\n",
    "            # Add OS/PFS info to explanation if available\n",
    "            os_imp_perc_orig = result.get('OS_Improvement (%)', 'N/A')\n",
    "            pfs_imp_perc_orig = result.get('PFS_Improvement (%)', 'N/A')\n",
    "\n",
    "            os_imp_str = \"\"\n",
    "            if result['calculated_os_improvement_months'] is not None:\n",
    "                 os_imp_str += f\"{result['calculated_os_improvement_months']:.2f} months difference (Treatment OS: {result.get('Treatment_OS', 'N/A')}, Control OS: {result.get('Control_OS', 'N/A')})\"\n",
    "            elif os_imp_perc_orig != 'N/A':\n",
    "                 os_imp_str += f\"OS Improvement: {os_imp_perc_orig}\"\n",
    "\n",
    "            if os_imp_str:\n",
    "                 explanation_parts.append(\"OS: \" + os_imp_str)\n",
    "\n",
    "            if pfs_imp_perc_orig != 'N/A':\n",
    "                 explanation_parts.append(f\"PFS Improvement: {pfs_imp_perc_orig}\")\n",
    "\n",
    "\n",
    "            formatted_output.append(f\"\\n--- Result {i+1} ---\")\n",
    "            formatted_output.append(f\"Drug Name: {result['Drug Name']}\")\n",
    "            formatted_output.append(f\"Cancer Type: {result['Cancer Type']}\") \n",
    "            formatted_output.append(f\"Summary: {result['Brief Study Summary']}\") \n",
    "\n",
    "            formatted_output.append(\"Explanation: \" + \" | \".join(explanation_parts))\n",
    "\n",
    "\n",
    "    print(\"\\n\".join(formatted_output))\n",
    "    return potential_results \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "4f586ed7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Please enter patient information for drug matching.\n",
      "\n",
      "--- Searching for drugs for profile: non-small cell lung cancer stage iv egfr mutation pd-l1 positive ---\n",
      "\n",
      "Found 17 potentially relevant drugs (Semantic Similarity >= 0.50):\n",
      "\n",
      "--- Result 1 ---\n",
      "Drug Name: Osimertinib (TAGRISSO)\n",
      "Cancer Type: Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations\n",
      "Summary: Osimertinib was approved for adjuvant therapy in NSCLC patients with specific mutations after tumor resection. The ADAURA trial showed a significant improvement in disease-free survival with osimertinib compared to placebo, leading to the FDA approval of the drug for this indication.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6659 | OS: nan months difference (Treatment OS: Median DFS not reached in the osimertinib arm, Control OS: Median DFS of 19.6 months in the placebo arm) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 2 ---\n",
      "Drug Name: Osimertinib (Tagrisso)\n",
      "Cancer Type: Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations\n",
      "Summary: Osimertinib in combination with platinum-based chemotherapy showed a significant improvement in progression-free survival (PFS) compared to osimertinib monotherapy in patients with EGFR-mutated NSCLC. Overall survival (OS) data is still immature, but no negative trend was observed. Common adverse reactions included leukopenia, thrombocytopenia, and rash. Osimertinib was granted priority review and other expedited designations by the FDA.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6659 | OS: nan months difference (Treatment OS: Data not mature, Control OS: Data not mature) | PFS Improvement: Approximately 52%\n",
      "\n",
      "--- Result 3 ---\n",
      "Drug Name: Amivantamab-vmjw (Rybrevant)\n",
      "Cancer Type: Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations\n",
      "Summary: Amivantamab-vmjw in combination with carboplatin and pemetrexed showed a significant improvement in progression-free survival compared to carboplatin and pemetrexed alone in patients with NSCLC with specific mutations. However, no statistically significant difference was observed in overall survival between the treatment and control arms. Common adverse reactions were manageable. Further regulatory reviews are ongoing internationally.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6654 | OS: nan months difference (Treatment OS: Data not provided, Control OS: Data not provided) | PFS Improvement: Hazard ratio 0.48 [95% CI: 0.36, 0.64], p-value<0.0001\n",
      "\n",
      "--- Result 4 ---\n",
      "Drug Name: Lazertinib in combination with amivantamab-vmjw\n",
      "Cancer Type: Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations\n",
      "Summary: The study evaluated the efficacy of lazertinib in combination with amivantamab-vmjw for the first-line treatment of locally advanced or metastatic NSCLC with specific mutations. The combination showed a statistically significant improvement in progression-free survival compared to the control arm. Overall survival results were immature at the time of analysis. Common adverse reactions included rash, nail toxicity, and infusion-related reactions. Venous thromboembolic events were observed as a serious safety signal. The study was conducted under Project Orbis for expedited review.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6654 | OS: nan months difference (Treatment OS: Data not provided, Control OS: Data not provided) | PFS Improvement: Data not provided\n",
      "\n",
      "--- Result 5 ---\n",
      "Drug Name: amivantamab-vmjw (Rybrevant)\n",
      "Cancer Type: non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations\n",
      "Summary: The FDA granted accelerated approval to amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The approval was based on the CHRYSALIS trial, which showed an overall response rate of 40% with a median response duration of 11.1 months. Common adverse reactions included rash, infusion-related reactions, and musculoskeletal pain.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6629 | OS: nan months difference (Treatment OS: Not provided, Control OS: Not provided) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 6 ---\n",
      "Drug Name: Osimertinib (Tagrisso)\n",
      "Cancer Type: Locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations\n",
      "Summary: Osimertinib (Tagrisso) was approved for locally advanced, unresectable non-small cell lung cancer with specific mutations. In a trial of 216 patients, osimertinib showed a significant improvement in progression-free survival compared to placebo. Overall survival results were immature at the time of analysis. Common adverse reactions included lymphopenia, leukopenia, and interstitial lung disease. The recommended dose is 80 mg once daily until disease progression or unacceptable toxicity.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6564 | OS: nan months difference (Treatment OS: Not available, Control OS: Not available) | PFS Improvement: Not available\n",
      "\n",
      "--- Result 7 ---\n",
      "Drug Name: Ramucirumab (CYRAMZA)\n",
      "Cancer Type: Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations\n",
      "Summary: Ramucirumab in combination with erlotinib showed a significant improvement in progression-free survival (PFS) compared to placebo plus erlotinib in patients with metastatic NSCLC with EGFR mutations. Overall survival (OS) data were not mature at the time of final analysis. Common adverse reactions included infections, hypertension, and stomatitis.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6502 | OS: nan months difference (Treatment OS: Data not mature at the time of final analysis, Control OS: Data not mature at the time of final analysis) | PFS Improvement: HR 0.59; 95% CI: 0.46, 0.76; p<0.0001\n",
      "\n",
      "--- Result 8 ---\n",
      "Drug Name: Mobocertinib (Exkivity)\n",
      "Cancer Type: Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations\n",
      "Summary: Mobocertinib (Exkivity) was granted accelerated approval by the FDA for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The approval was based on Study 101, which showed an overall response rate of 28% and a median response duration of 17.5 months in 114 patients. Common adverse reactions included diarrhea, rash, nausea, and others. The recommended dose is 160 mg orally daily until disease progression or intolerable toxicity.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6499 | OS: nan months difference (Treatment OS: Not provided, Control OS: Not provided) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 9 ---\n",
      "Drug Name: Amivantamab-vmjw (Rybrevant)\n",
      "Cancer Type: Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations\n",
      "Summary: Amivantamab-vmjw with carboplatin and pemetrexed showed a significant improvement in progression-free survival (PFS) compared to carboplatin and pemetrexed in patients with NSCLC with EGFR exon 20 insertion mutations. Overall survival (OS) data is immature, but no trend towards detriment was observed. Common adverse reactions included rash, nail toxicity, and stomatitis.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.6499 | OS: nan months difference (Treatment OS: Data immature, Control OS: Data immature) | PFS Improvement: 69.40%\n",
      "\n",
      "--- Result 10 ---\n",
      "Drug Name: Durvalumab (Imfinzi)\n",
      "Cancer Type: Limited-stage small cell lung cancer (LS-SCLC)\n",
      "Summary: Durvalumab demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease had not progressed following concurrent platinum-based chemotherapy and radiation therapy. The median OS was 55.9 months with durvalumab compared to 33.4 months with placebo, and the median PFS was 16.6 months with durvalumab compared to 9.2 months with placebo. Common adverse reactions included pneumonitis or radiation pneumonitis and fatigue.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5677 | OS: 22.50 months difference (Treatment OS: 55.9 months, Control OS: 33.4 months) | PFS Improvement: 80.40%\n",
      "\n",
      "--- Result 11 ---\n",
      "Drug Name: Durvalumab\n",
      "Cancer Type: Extensive-stage small cell lung cancer (ES-SCLC)\n",
      "Summary: Durvalumab in combination with chemotherapy showed a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). The treatment arm demonstrated a 26.2% improvement in OS and a 5.6% improvement in PFS. Additionally, the objective response rate (ORR) was 68% in the durvalumab plus chemotherapy arm.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5653 | OS: 2.70 months difference (Treatment OS: 13.0 months, Control OS: 10.3 months) | PFS Improvement: 5.60%\n",
      "\n",
      "--- Result 12 ---\n",
      "Drug Name: Tarlatamab-dlle (Imdelltra)\n",
      "Cancer Type: Extensive stage small cell lung cancer (ES-SCLC)\n",
      "Summary: Tarlatamab-dlle (Imdelltra) received accelerated approval for ES-SCLC with disease progression after platinum-based chemotherapy. The study included 99 patients and showed an overall response rate of 40% with a median duration of response of 9.7 months. The drug comes with a Boxed Warning for cytokine release syndrome and neurologic toxicity. FDA granted accelerated approval based on response rate and duration of response, with continued approval contingent upon verification of clinical benefit.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5632 | OS: nan months difference (Treatment OS: Not provided, Control OS: Not provided) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 13 ---\n",
      "Drug Name: Nivolumab plus Ipilimumab\n",
      "Cancer Type: Metastatic non-small cell lung cancer\n",
      "Summary: The combination of nivolumab plus ipilimumab showed a statistically significant improvement in overall survival and progression-free survival compared to platinum-doublet chemotherapy in patients with metastatic non-small cell lung cancer expressing PD-L1(≥1%). The treatment arm demonstrated a 13.4% improvement in overall survival and an 8.9% improvement in progression-free survival, with an overall response rate of 36% and a median response duration of 23.2 months.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5257 | OS: 2.20 months difference (Treatment OS: 17.1 months, Control OS: 14.9 months) | PFS Improvement: 8.90%\n",
      "\n",
      "--- Result 14 ---\n",
      "Drug Name: Capmatinib (Tabrecta)\n",
      "Cancer Type: Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation\n",
      "Summary: Capmatinib (Tabrecta) was granted regular approval for adult patients with metastatic NSCLC with MET exon 14 skipping mutation. Efficacy was demonstrated in 160 patients, showing high ORR in treatment-naïve and previously treated patients. Common adverse reactions included edema, nausea, musculoskeletal pain, and fatigue. The recommended dose is 400 mg orally twice daily. The study conversion to regular approval was based on additional patient data and follow-up time to assess durability of response and clinical benefit.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5117 | OS: nan months difference (Treatment OS: Not provided, Control OS: Not provided) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 15 ---\n",
      "Drug Name: Capmatinib (TABRECTA)\n",
      "Cancer Type: Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation\n",
      "Summary: Capmatinib (TABRECTA) was granted accelerated approval for metastatic NSCLC with MET exon 14 skipping mutation. Efficacy was demonstrated in a trial with 97 patients showing ORR of 68% in treatment-naïve and 41% in previously treated patients. Common adverse reactions include peripheral edema, nausea, and fatigue. Safety concerns include interstitial lung disease and hepatotoxicity. Continued approval may be contingent upon confirmatory trials.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5117 | OS: nan months difference (Treatment OS: Not provided, Control OS: Not provided) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 16 ---\n",
      "Drug Name: Alectinib (Alecensa)\n",
      "Cancer Type: Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)\n",
      "Summary: Alectinib was approved for adjuvant treatment in ALK-positive NSCLC patients post-tumor resection. In a randomized trial, alectinib showed significant improvement in disease-free survival compared to chemotherapy. Common adverse reactions included hepatotoxicity, constipation, myalgia, and fatigue. The recommended dose is 600 mg orally twice daily for 2 years or until disease recurrence or unacceptable toxicity.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5075 | OS: nan months difference (Treatment OS: Median DFS not reached in alectinib arm, Control OS: 44.4 months in chemotherapy arm) | PFS Improvement: Not provided\n",
      "\n",
      "--- Result 17 ---\n",
      "Drug Name: Brigatinib\n",
      "Cancer Type: Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)\n",
      "Summary: Brigatinib was approved for ALK-positive metastatic NSCLC. In a trial of 275 patients, brigatinib showed a significant improvement in progression-free survival compared to crizotinib. The confirmed overall response rate was also higher with brigatinib. Common adverse reactions included diarrhea, fatigue, and nausea.\n",
      "Explanation: Relevance Score (Semantic Sim): 0.5031 | OS: nan months difference (Treatment OS: Not provided, Control OS: Not provided) | PFS Improvement: HR 0.49; 95% CI: 0.35, 0.68; p<.0001\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'index': 122,\n",
       "  'semantic_similarity': np.float32(0.66592246),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Osimertinib (TAGRISSO)',\n",
       "  'Cancer Type': 'Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations',\n",
       "  'Brief Study Summary': 'Osimertinib was approved for adjuvant therapy in NSCLC patients with specific mutations after tumor resection. The ADAURA trial showed a significant improvement in disease-free survival with osimertinib compared to placebo, leading to the FDA approval of the drug for this indication.',\n",
       "  'Treatment_OS': 'Median DFS not reached in the osimertinib arm',\n",
       "  'Control_OS': 'Median DFS of 19.6 months in the placebo arm',\n",
       "  'OS_Improvement (%)': 'HR 0.17 (95% CI: 0.12, 0.23; <0.0001)',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 226,\n",
       "  'semantic_similarity': np.float32(0.66592246),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Osimertinib (Tagrisso)',\n",
       "  'Cancer Type': 'Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations',\n",
       "  'Brief Study Summary': 'Osimertinib in combination with platinum-based chemotherapy showed a significant improvement in progression-free survival (PFS) compared to osimertinib monotherapy in patients with EGFR-mutated NSCLC. Overall survival (OS) data is still immature, but no negative trend was observed. Common adverse reactions included leukopenia, thrombocytopenia, and rash. Osimertinib was granted priority review and other expedited designations by the FDA.',\n",
       "  'Treatment_OS': 'Data not mature',\n",
       "  'Control_OS': 'Data not mature',\n",
       "  'OS_Improvement (%)': 'Data not available',\n",
       "  'Treatment_PFS': '25.5 months (95% CI: 24.7, NE)',\n",
       "  'Control_PFS': '16.7 months (95% CI: 14.1, 21.3)',\n",
       "  'PFS_Improvement (%)': 'Approximately 52%'},\n",
       " {'index': 135,\n",
       "  'semantic_similarity': np.float32(0.6653945),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Amivantamab-vmjw (Rybrevant)',\n",
       "  'Cancer Type': 'Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations',\n",
       "  'Brief Study Summary': 'Amivantamab-vmjw in combination with carboplatin and pemetrexed showed a significant improvement in progression-free survival compared to carboplatin and pemetrexed alone in patients with NSCLC with specific mutations. However, no statistically significant difference was observed in overall survival between the treatment and control arms. Common adverse reactions were manageable. Further regulatory reviews are ongoing internationally.',\n",
       "  'Treatment_OS': 'Data not provided',\n",
       "  'Control_OS': 'Data not provided',\n",
       "  'OS_Improvement (%)': 'Data not provided',\n",
       "  'Treatment_PFS': '6.3 months (95% CI: 5.6, 8.4)',\n",
       "  'Control_PFS': '4.2 months (95% CI: 4.0, 4.4)',\n",
       "  'PFS_Improvement (%)': 'Hazard ratio 0.48 [95% CI: 0.36, 0.64], p-value<0.0001'},\n",
       " {'index': 179,\n",
       "  'semantic_similarity': np.float32(0.6653945),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Lazertinib in combination with amivantamab-vmjw',\n",
       "  'Cancer Type': 'Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations',\n",
       "  'Brief Study Summary': 'The study evaluated the efficacy of lazertinib in combination with amivantamab-vmjw for the first-line treatment of locally advanced or metastatic NSCLC with specific mutations. The combination showed a statistically significant improvement in progression-free survival compared to the control arm. Overall survival results were immature at the time of analysis. Common adverse reactions included rash, nail toxicity, and infusion-related reactions. Venous thromboembolic events were observed as a serious safety signal. The study was conducted under Project Orbis for expedited review.',\n",
       "  'Treatment_OS': 'Data not provided',\n",
       "  'Control_OS': 'Data not provided',\n",
       "  'OS_Improvement (%)': 'Data not provided',\n",
       "  'Treatment_PFS': '23.7 months (95% CI: 19.1, 27.7)',\n",
       "  'Control_PFS': '16.6 months (95% CI: 14.8, 18.5)',\n",
       "  'PFS_Improvement (%)': 'Data not provided'},\n",
       " {'index': 94,\n",
       "  'semantic_similarity': np.float32(0.66290927),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'amivantamab-vmjw (Rybrevant)',\n",
       "  'Cancer Type': 'non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations',\n",
       "  'Brief Study Summary': 'The FDA granted accelerated approval to amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The approval was based on the CHRYSALIS trial, which showed an overall response rate of 40% with a median response duration of 11.1 months. Common adverse reactions included rash, infusion-related reactions, and musculoskeletal pain.',\n",
       "  'Treatment_OS': 'Not provided',\n",
       "  'Control_OS': 'Not provided',\n",
       "  'OS_Improvement (%)': 'Not provided',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 113,\n",
       "  'semantic_similarity': np.float32(0.656404),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Osimertinib (Tagrisso)',\n",
       "  'Cancer Type': 'Locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations',\n",
       "  'Brief Study Summary': 'Osimertinib (Tagrisso) was approved for locally advanced, unresectable non-small cell lung cancer with specific mutations. In a trial of 216 patients, osimertinib showed a significant improvement in progression-free survival compared to placebo. Overall survival results were immature at the time of analysis. Common adverse reactions included lymphopenia, leukopenia, and interstitial lung disease. The recommended dose is 80 mg once daily until disease progression or unacceptable toxicity.',\n",
       "  'Treatment_OS': 'Not available',\n",
       "  'Control_OS': 'Not available',\n",
       "  'OS_Improvement (%)': 'Not available',\n",
       "  'Treatment_PFS': '39.1 months',\n",
       "  'Control_PFS': '5.6 months',\n",
       "  'PFS_Improvement (%)': 'Not available'},\n",
       " {'index': 159,\n",
       "  'semantic_similarity': np.float32(0.65019894),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Ramucirumab (CYRAMZA)',\n",
       "  'Cancer Type': 'Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations',\n",
       "  'Brief Study Summary': 'Ramucirumab in combination with erlotinib showed a significant improvement in progression-free survival (PFS) compared to placebo plus erlotinib in patients with metastatic NSCLC with EGFR mutations. Overall survival (OS) data were not mature at the time of final analysis. Common adverse reactions included infections, hypertension, and stomatitis.',\n",
       "  'Treatment_OS': 'Data not mature at the time of final analysis',\n",
       "  'Control_OS': 'Data not mature at the time of final analysis',\n",
       "  'OS_Improvement (%)': 'Data not mature at the time of final analysis',\n",
       "  'Treatment_PFS': '19.4 months',\n",
       "  'Control_PFS': '12.4 months',\n",
       "  'PFS_Improvement (%)': 'HR 0.59; 95% CI: 0.46, 0.76; p<0.0001'},\n",
       " {'index': 75,\n",
       "  'semantic_similarity': np.float32(0.64992714),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Mobocertinib (Exkivity)',\n",
       "  'Cancer Type': 'Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations',\n",
       "  'Brief Study Summary': 'Mobocertinib (Exkivity) was granted accelerated approval by the FDA for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The approval was based on Study 101, which showed an overall response rate of 28% and a median response duration of 17.5 months in 114 patients. Common adverse reactions included diarrhea, rash, nausea, and others. The recommended dose is 160 mg orally daily until disease progression or intolerable toxicity.',\n",
       "  'Treatment_OS': 'Not provided',\n",
       "  'Control_OS': 'Not provided',\n",
       "  'OS_Improvement (%)': 'Not provided',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 225,\n",
       "  'semantic_similarity': np.float32(0.64992714),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': 69.4,\n",
       "  'Drug Name': 'Amivantamab-vmjw (Rybrevant)',\n",
       "  'Cancer Type': 'Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations',\n",
       "  'Brief Study Summary': 'Amivantamab-vmjw with carboplatin and pemetrexed showed a significant improvement in progression-free survival (PFS) compared to carboplatin and pemetrexed in patients with NSCLC with EGFR exon 20 insertion mutations. Overall survival (OS) data is immature, but no trend towards detriment was observed. Common adverse reactions included rash, nail toxicity, and stomatitis.',\n",
       "  'Treatment_OS': 'Data immature',\n",
       "  'Control_OS': 'Data immature',\n",
       "  'OS_Improvement (%)': 'Data immature',\n",
       "  'Treatment_PFS': '11.4 months',\n",
       "  'Control_PFS': '6.7 months',\n",
       "  'PFS_Improvement (%)': '69.40%'},\n",
       " {'index': 261,\n",
       "  'semantic_similarity': np.float32(0.56770873),\n",
       "  'calculated_os_improvement_months': 22.5,\n",
       "  'os_improvement_percentage_parsed': 67.1,\n",
       "  'pfs_improvement_percentage_parsed': 80.4,\n",
       "  'Drug Name': 'Durvalumab (Imfinzi)',\n",
       "  'Cancer Type': 'Limited-stage small cell lung cancer (LS-SCLC)',\n",
       "  'Brief Study Summary': 'Durvalumab demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease had not progressed following concurrent platinum-based chemotherapy and radiation therapy. The median OS was 55.9 months with durvalumab compared to 33.4 months with placebo, and the median PFS was 16.6 months with durvalumab compared to 9.2 months with placebo. Common adverse reactions included pneumonitis or radiation pneumonitis and fatigue.',\n",
       "  'Treatment_OS': '55.9 months',\n",
       "  'Control_OS': '33.4 months',\n",
       "  'OS_Improvement (%)': '67.10%',\n",
       "  'Treatment_PFS': '16.6 months',\n",
       "  'Control_PFS': '9.2 months',\n",
       "  'PFS_Improvement (%)': '80.40%'},\n",
       " {'index': 185,\n",
       "  'semantic_similarity': np.float32(0.56533283),\n",
       "  'calculated_os_improvement_months': 2.6999999999999993,\n",
       "  'os_improvement_percentage_parsed': 26.2,\n",
       "  'pfs_improvement_percentage_parsed': 5.6,\n",
       "  'Drug Name': 'Durvalumab',\n",
       "  'Cancer Type': 'Extensive-stage small cell lung cancer (ES-SCLC)',\n",
       "  'Brief Study Summary': 'Durvalumab in combination with chemotherapy showed a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). The treatment arm demonstrated a 26.2% improvement in OS and a 5.6% improvement in PFS. Additionally, the objective response rate (ORR) was 68% in the durvalumab plus chemotherapy arm.',\n",
       "  'Treatment_OS': '13.0 months',\n",
       "  'Control_OS': '10.3 months',\n",
       "  'OS_Improvement (%)': '26.20%',\n",
       "  'Treatment_PFS': '5.1 months',\n",
       "  'Control_PFS': '5.4 months',\n",
       "  'PFS_Improvement (%)': '5.60%'},\n",
       " {'index': 210,\n",
       "  'semantic_similarity': np.float32(0.5632246),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Tarlatamab-dlle (Imdelltra)',\n",
       "  'Cancer Type': 'Extensive stage small cell lung cancer (ES-SCLC)',\n",
       "  'Brief Study Summary': 'Tarlatamab-dlle (Imdelltra) received accelerated approval for ES-SCLC with disease progression after platinum-based chemotherapy. The study included 99 patients and showed an overall response rate of 40% with a median duration of response of 9.7 months. The drug comes with a Boxed Warning for cytokine release syndrome and neurologic toxicity. FDA granted accelerated approval based on response rate and duration of response, with continued approval contingent upon verification of clinical benefit.',\n",
       "  'Treatment_OS': 'Not provided',\n",
       "  'Control_OS': 'Not provided',\n",
       "  'OS_Improvement (%)': 'Not provided',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 167,\n",
       "  'semantic_similarity': np.float32(0.5256619),\n",
       "  'calculated_os_improvement_months': 2.200000000000001,\n",
       "  'os_improvement_percentage_parsed': 13.4,\n",
       "  'pfs_improvement_percentage_parsed': 8.9,\n",
       "  'Drug Name': 'Nivolumab plus Ipilimumab',\n",
       "  'Cancer Type': 'Metastatic non-small cell lung cancer',\n",
       "  'Brief Study Summary': 'The combination of nivolumab plus ipilimumab showed a statistically significant improvement in overall survival and progression-free survival compared to platinum-doublet chemotherapy in patients with metastatic non-small cell lung cancer expressing PD-L1(≥1%). The treatment arm demonstrated a 13.4% improvement in overall survival and an 8.9% improvement in progression-free survival, with an overall response rate of 36% and a median response duration of 23.2 months.',\n",
       "  'Treatment_OS': '17.1 months',\n",
       "  'Control_OS': '14.9 months',\n",
       "  'OS_Improvement (%)': '13.40%',\n",
       "  'Treatment_PFS': '5.1 months',\n",
       "  'Control_PFS': '5.6 months',\n",
       "  'PFS_Improvement (%)': '8.90%'},\n",
       " {'index': 36,\n",
       "  'semantic_similarity': np.float32(0.5116799),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Capmatinib (Tabrecta)',\n",
       "  'Cancer Type': 'Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation',\n",
       "  'Brief Study Summary': 'Capmatinib (Tabrecta) was granted regular approval for adult patients with metastatic NSCLC with MET exon 14 skipping mutation. Efficacy was demonstrated in 160 patients, showing high ORR in treatment-naïve and previously treated patients. Common adverse reactions included edema, nausea, musculoskeletal pain, and fatigue. The recommended dose is 400 mg orally twice daily. The study conversion to regular approval was based on additional patient data and follow-up time to assess durability of response and clinical benefit.',\n",
       "  'Treatment_OS': 'Not provided',\n",
       "  'Control_OS': 'Not provided',\n",
       "  'OS_Improvement (%)': 'Not provided',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 172,\n",
       "  'semantic_similarity': np.float32(0.5116799),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Capmatinib (TABRECTA)',\n",
       "  'Cancer Type': 'Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation',\n",
       "  'Brief Study Summary': 'Capmatinib (TABRECTA) was granted accelerated approval for metastatic NSCLC with MET exon 14 skipping mutation. Efficacy was demonstrated in a trial with 97 patients showing ORR of 68% in treatment-naïve and 41% in previously treated patients. Common adverse reactions include peripheral edema, nausea, and fatigue. Safety concerns include interstitial lung disease and hepatotoxicity. Continued approval may be contingent upon confirmatory trials.',\n",
       "  'Treatment_OS': 'Not provided',\n",
       "  'Control_OS': 'Not provided',\n",
       "  'OS_Improvement (%)': 'Not provided',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 216,\n",
       "  'semantic_similarity': np.float32(0.50751626),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Alectinib (Alecensa)',\n",
       "  'Cancer Type': 'Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)',\n",
       "  'Brief Study Summary': 'Alectinib was approved for adjuvant treatment in ALK-positive NSCLC patients post-tumor resection. In a randomized trial, alectinib showed significant improvement in disease-free survival compared to chemotherapy. Common adverse reactions included hepatotoxicity, constipation, myalgia, and fatigue. The recommended dose is 600 mg orally twice daily for 2 years or until disease recurrence or unacceptable toxicity.',\n",
       "  'Treatment_OS': 'Median DFS not reached in alectinib arm',\n",
       "  'Control_OS': '44.4 months in chemotherapy arm',\n",
       "  'OS_Improvement (%)': 'HR 0.24 [95% CI: 0.13, 0.45]; p<0.0001',\n",
       "  'Treatment_PFS': 'Not provided',\n",
       "  'Control_PFS': 'Not provided',\n",
       "  'PFS_Improvement (%)': 'Not provided'},\n",
       " {'index': 162,\n",
       "  'semantic_similarity': np.float32(0.5031409),\n",
       "  'calculated_os_improvement_months': nan,\n",
       "  'os_improvement_percentage_parsed': nan,\n",
       "  'pfs_improvement_percentage_parsed': nan,\n",
       "  'Drug Name': 'Brigatinib',\n",
       "  'Cancer Type': 'Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)',\n",
       "  'Brief Study Summary': 'Brigatinib was approved for ALK-positive metastatic NSCLC. In a trial of 275 patients, brigatinib showed a significant improvement in progression-free survival compared to crizotinib. The confirmed overall response rate was also higher with brigatinib. Common adverse reactions included diarrhea, fatigue, and nausea.',\n",
       "  'Treatment_OS': 'Not provided',\n",
       "  'Control_OS': 'Not provided',\n",
       "  'OS_Improvement (%)': 'Not provided',\n",
       "  'Treatment_PFS': '24 months (95% CI: 18.5, NE)',\n",
       "  'Control_PFS': '11 months (95% CI: 9.2, 12.9)',\n",
       "  'PFS_Improvement (%)': 'HR 0.49; 95% CI: 0.35, 0.68; p<.0001'}]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "# --- TESTING\n",
    "\n",
    "print(\"\\nPlease enter patient information for drug matching.\")\n",
    "\n",
    "# --- TEst 1\n",
    "# user_cancer_type = \"HR-positive, HER2-negative breast cancer\"\n",
    "# user_stage = \"metastatic\"\n",
    "# user_biomarkers = \"\" # Testing biomarker match\n",
    "\n",
    "# find_relevant_drugs(df, drug_embeddings, model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "\n",
    "# --- Test 2: A \n",
    "user_cancer_type = \"Non-Small Cell Lung Cancer\"\n",
    "user_stage = \"Stage IV\"\n",
    "user_biomarkers = \"EGFR mutation, PD-L1 positive\"\n",
    "\n",
    "find_relevant_drugs(df, drug_embeddings, model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "\n",
    "# --- Test 3:\n",
    "# user_cancer_type = \"Melanoma\"\n",
    "# user_stage = \"advanced unresectable\"\n",
    "# user_biomarkers = \"BRAF V600E mutation\"\n",
    "\n",
    "# find_relevant_drugs(df, drug_embeddings, model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "\n",
    "\n",
    "# --- Test 5\n",
    "# user_cancer_type = \"Prostate cancer\"\n",
    "# user_stage = \"metastatic castration-resistant\"\n",
    "# user_biomarkers = \"PSMA-positive, mCRPC\"\n",
    "\n",
    "# find_relevant_drugs(df, drug_embeddings, model, user_cancer_type, user_stage, user_biomarkers)\n",
    "\n",
    "\n",
    "# --- Test 6\n",
    "# user_cancer_type = \"NSCLC\"\n",
    "# user_stage = \"Stage 4 lung cancer\"\n",
    "# user_biomarkers = \"PDL1 high\"\n",
    "\n",
    "# find_relevant_drugs(df, drug_embeddings, model, user_cancer_type, user_stage, user_biomarkers)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
